Outlook Therapeutics (NASDAQ:OTLK) reported its fiscal 2025 results for the year ended September 30, 2025, revealing a net loss of $62.4 million ($1.79 per share) and $1.4 million in revenue from the initial European sales of LYTENAVA in June 2025.
The gross profit was impacted by increased reserves for short-dated inventory from shipments to the UK.
Operating expenses saw a year-over-year decline due to lower R&D costs following the completion of the NORSE Eight clinical trial, although these were offset by higher SG&A expenses related to the European launch of LYTENAVA.
As of September 30, 2025, the company reported cash and equivalents of $8.1 million, with an additional $14.9 million in net proceeds received after the period from its at-the-market (ATM) offering.
Looking ahead, Outlook Therapeutics highlighted the FDA PDUFA goal date for ONS-5010, set for December 31, 2025, marking a crucial milestone for the company’s regulatory progress